Related Experiment Videos

Addition of macrolide in treating adult hospitalized community-acquired pneumonia

Li-Cher Loh1, Soong-Yuen Quah, Sert-Kim Khoo

  • 1IMU Lung Research, International Medical University, Kuala Lumpur, Malalysia. loh@imu.edu.my

Respirology (Carlton, Vic.)
|June 16, 2005
PubMed
Abstract

Insights

Adding macrolides to antibiotics for community-acquired pneumonia (CAP) in hospitalized adults showed no significant clinical benefit. This observational study found no difference in mortality, ventilation needs, or hospital stay duration with macrolide addition.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Clinical Pharmacology

Background:

  • Current guidelines recommend macrolides plus broad-spectrum antibiotics for severe community-acquired pneumonia (CAP).
  • The clinical utility of this combined approach in hospitalized adult CAP patients requires further investigation.

Purpose of the Study:

  • To evaluate the impact of adding a macrolide antibiotic on clinical outcomes in hospitalized adult patients diagnosed with CAP.
  • To compare treatment regimens with and without macrolide supplementation.

Main Methods:

  • Prospective observational study involving 141 adult CAP patients over 16 months.
  • Patients were divided into two groups: one receiving macrolide-containing regimens and the other receiving single broad-spectrum antibiotics.
  • Outcomes assessed included mortality, need for ventilation, and length of hospital stay.

Main Results:

  • No statistically significant differences were observed in mortality rates between the two groups for both severe and non-severe CAP.
  • The need for mechanical ventilation and the median length of hospital stay did not differ significantly between patients receiving macrolides and those who did not.
  • These findings held true irrespective of pneumonia severity.

Conclusions:

  • The addition of macrolides to standard antibiotic treatment for hospitalized adult CAP patients may not offer additional clinical advantages.
  • Results suggest current guideline recommendations for macrolide addition may warrant re-evaluation based on this evidence.
  • Further research, potentially including randomized controlled trials, could confirm these findings.

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...